Page 120 - Recognizing axial spondyloarthritis - Janneke de Winter

CHAPTER SEVEN
Study population
51 (100)
2 (4) 2 (4) 6 (12)
1 (2)
7 (11) 11 (16) 5 (14)
1.17 (1.30)
3 (6)
0.41 (0.49)
3 (6)
0.43 (0.77)
6.43 (6.21) 11 (22) 6.26 (2.48) 2 (4)
2.16 (0.76)
8 (16) 0 (0) 10 (20) 0 (0)
0 (0) 0 (0)
Fulfilling the ASAS axSpA and/or ESSG criteria
Fulfilling vs not fulfilling the ASAS axSpA and/or ESSG criteria
-
0.043 0.312 0.361
0.480
<0.001 0.065 0.003
<0.001
0.211 0.007
0.211 0.001
0.571
0.336
0.628
0.614
0.098
0.059 - 0.007 -
- -
Family history
Ankylosing spondylitis
Psoriatic arthritis Psoriasis
Inflammatory bowel disease
Uveitis
Disease activity measurements
PhGA, 0-100mm VAS, mean (SD)
PGA, 0-100mmVAS, mean (SD)
Patient nocturnal pain, 0-100mm VAS, mean (SD)
BASDAI, 0-10cm, mean (SD)
BASDAI >4 ASDAS-CRP, mean (SD)
ASDAS-CRP ≥1.3 BASFI, 0-10cm, mean (SD)
Clinical examination
modified Schober, cm, mean (SD)
modified Schober <4.5cm
Chest expansion, cm, mean (SD)
Chest expansion <3.6cm
BASMI, 0-10, mean (SD)
TJC > 0, 0-68 joints
SJC > 0, 0-66 joints MASES>0
Dactylitis, presence Nail psoriasis, presence Psoriasis, presence
17 (100)
2 (12) 0 (0) 3 (18)
0 (0)
12 (3) 15 (18) 13 (22)
2.04 (1.42)
2 (12) 0.67 (0.59)
2 (12) 0.85 (1.08)
5.79 (4.03) 5 (29) 5.97 (2.25) 1 (6)
2.35 (0.93)
5 (29) 0 (0) 7 (41) 0 (0) 0 (0) 0 (0)
34 (100)
0 (0) 2 (6) 3 (9)
1 (3)
4 (9) 8 (15) 2 (3)
0.73 (1.00)
1 (3)
0.27 (0.38)
1 (3)
0.22 (0.46)
6.62 (7.09) 6 (18) 6.04 (2.61) 1 (3)
2.06 (0.65)
3 (9) 0 (0) 3 (9) 0 (0) 0 (0) 0 (0)
Table 1 continues
118